Relief therapeutics « Terug naar discussie overzicht

Relief therapeutics Holding

8.668 Posts, Pagina: « 1 2 3 4 5 6 ... 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 » | Laatste
Gerardke
1
quote:

Gerardke schreef op 30 augustus 2021 17:22:


[...]

DeZwarteRidder 6 augustus 2021 14:31

Humanigen wacht op goedkeuring FDA
Humanigen (HGEN) op $16

Wie van een beetje avontuur houdt kan met het aandeel Humanigen mikken op een goedkeuring van de FDA. We geven rond uit toe dat het speculatief is. Verkopen doet u bij teleurstelling, maar ook bij de eerste euforie. Dit aandeel is geen kernbelegging, maar interessant is het zeker.

....yeps...


Jouw avontuurtje met Humanigen is alvast gedaan , Weeral slecht advies van jou !!
Humanigen Inc. has added a new press release to its website:

FDA has declined Humanigen’s Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients
Beso
0
quote:

DeZwarteRidder schreef op 8 september 2021 08:32:


[...]
Deze dumpovereenkomst met GEM gaat dus niet door, want Relief en GEM hebben grote ruzie.
GEM zou met een vaste winst van 10% tot 50 miljoen CHF aandelen mogen dumpen.

Door de koersdaling worden dat theoretisch ca 2% meer aandelen, maar in werkelijkheid krijgt GEM geen enkel aandeel erbij.

In plaats van deze dumpdeal is Relief nu zelf bezig om bijna dagelijks aandelen te dumpen.

Waar heb je die info dat GEM en RLF grote ruzie hebben?
Bron?
Ik heb enkel weet van RLF versus NRX maar niet met GEM
DeZwarteRidder
0
quote:

Beso schreef op 9 september 2021 09:41:


[...]
Waar heb je die info dat GEM en RLF grote ruzie hebben?
Bron?
Ik heb enkel weet van RLF versus NRX maar niet met GEM


Dat gaan ze niet aan de grote klok hangen, maar het is volkomen duidelijk voor mij.

Relief is zo boos op GEM dat ze zelf aandelen gaan dumpen op de beurs, terwijl ze een deal hadden met GEM.

De dumpdeal met GEM is dus waardeloos geworden en bovendien daalt de waarde van de Relief-aandelen door het gedump van Relief.

Tenslotte heeft GEM NRX in contact gebracht met Relief.
DeZwarteRidder
0
quote:

Gerardke schreef op 9 september 2021 07:35:


[...]
Jouw avontuurtje met Humanigen is alvast gedaan , Weeral slecht advies van jou !!
Humanigen Inc. has added a new press release to its website:

FDA has declined Humanigen’s Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients


Ik heb geen enkel 'advies' gegeven inzake Humanigen. Ik volg het niet eens.

Ik heb alleen een artikel geplaatst van iemand anders over een concurrent van Relief.
Gerardke
0
quote:

DeZwarteRidder schreef op 9 september 2021 10:02:


[...]

Dat gaan ze niet aan de grote klok hangen, maar het is volkomen duidelijk voor mij.

Relief is zo boos op GEM dat ze zelf aandelen gaan dumpen op de beurs, terwijl ze een deal hadden met GEM.

De dumpdeal met GEM is dus waardeloos geworden en bovendien daalt de waarde van de Relief-aandelen door het gedump van Relief.

Tenslotte heeft GEM NRX in contact gebracht met Relief.


Zij vertellen dus niets , maar jij weet het ? Van wie ? Waarom
5 verkopen gedaan van 18000 € /stuk .. dat is dumpen .. wacht dan tot ik mijn aandelen verkoop ;-)))

En Relief is boos op Gem en daarom dumpen ze hun eigen aandelen ?? Gekker gaat het niet worden
Gerardke
1
Humanigen heeft drie dagen voor Relief EUA aangevraagd.
We zullen het binnenkort dus wel horen.
Relief staat er trouwens veel beter voor , op wat diarree na ;-)
DeZwarteRidder
0
quote:

Gerardke schreef op 9 september 2021 12:54:


[...]Zij vertellen dus niets , maar jij weet het ? Van wie ? Waarom
5 verkopen gedaan van 18000 € /stuk .. dat is dumpen .. wacht dan tot ik mijn aandelen verkoop ;-)))
En Relief is boos op Gem en daarom dumpen ze hun eigen aandelen ?? Gekker gaat het niet worden

Ik kan wel zien dat jij weinig inzicht hebt in dit soort zaken.

Je moet tussen de regels door lezen.

De berichten zijn voor mij glashelder.
DeZwarteRidder
0

Management Transactions

Data submitted by listed companies regarding management transactions.

Type of Transaction
10 results

03.09.2021
RELIEF THERAPEUTICS Holding SA
Sale
Registered shares
79'094
CHF 14'158.00

26.08.2021
RELIEF THERAPEUTICS Holding SA
Sale
Registered shares
100'000
CHF 18'500.00

25.08.2021
RELIEF THERAPEUTICS Holding SA
Sale
Registered shares
100'000
CHF 18'500.00

24.08.2021
RELIEF THERAPEUTICS Holding SA
Sale
Registered shares
100'000
CHF 18'550.00

23.08.2021
RELIEF THERAPEUTICS Holding SA
Sale
Registered shares
100'000
CHF 18'500.00

20.08.2021
RELIEF THERAPEUTICS Holding SA
Sale
Registered shares
100'000
CHF 18'500.00

19.08.2021
RELIEF THERAPEUTICS Holding SA
Sale
Registered shares
100'000
CHF 19'900.00

18.08.2021
RELIEF THERAPEUTICS Holding SA
Sale
Registered shares
100'000
CHF 18'500.00

17.08.2021
RELIEF THERAPEUTICS Holding SA
Sale
Registered shares
100'000
CHF 18'500.00

10.08.2021
RELIEF THERAPEUTICS Holding SA
Sale
Registered shares
500'000
CHF 105'066.55

© 2020 SIX Exchange
DeZwarteRidder
0
Relief heeft nog 574'903'701 (13.065%) eigen aandelen in bezit die allemaal gedumpt gaan worden omdat Relief geld nodig heeft om de salarissen te betalen.
Gerardke
0
quote:

DeZwarteRidder schreef op 9 september 2021 13:09:


Relief heeft nog 574'903'701 (13.065%) eigen aandelen in bezit die allemaal gedumpt gaan worden omdat Relief geld nodig heeft om de salarissen te betalen.


antwoord van Relief :

Michael Miller
18:14 (31 minuten geleden)
aan mij, contact@relieftherapeutics.com, Relief

Please see the link to a press release explaining the plan to sell treasury shares



relieftherapeutics.com/newsblog/relie...



Board of Directors approved an increase of the Company's registered share capital from 3,246,727,248 to 3,371,727,248 shares through the issuance of 125,000,000 shares at an issue price of CHF 0.01. The 125,000,000 new shares, to be issued out of the Company’s authorized capital, are fully subscribed for by Relief Therapeutics International SA, its 100% wholly owned subsidiary, and will be listed on the SIX Swiss Exchange on or around March 11, 2021. Execution of the transaction will provide Relief with treasury shares, offering greater financial flexibility to raise funds in an efficient manner and in line with its equity plans for the Company and its subsidiaries.

Michael K. Miller

Vice President Investor Relations

917.633.6086 Direct

203.536.8136 Mobile

mmiller@rxir.com

Rx Communications Group, LLC

DeZwarteRidder
0
Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita

Acquisition Expands Scope of Development of Inhaled Formulation of Aviptadil

Geneva, Switzerland, July 28, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that it has closed a definitive agreement to acquire all outstanding shares of AdVita Lifescience GmbH ("AdVita"), a Germany-based, privately held pharmaceutical company developing effective products and strategies to improve the treatment and diagnosis of rare lung diseases.

With the acquisition, Relief has gained additional pending intellectual property rights that may cover RLF-100TM inhaled formulation specifications and the potential application of inhaled aviptadil for the treatment of lung diseases such as acute respiratory distress syndrome (ARDS), pulmonary sarcoidosis and checkpoint inhibitor-induced pneumonitis (CIP).

Under the terms of the agreement, Relief paid AdVita shareholders a total of 135,741,063 Relief common shares, representing EUR 25 million in value based on a 60-day Volume-Weighted Average Price (VWAP) of Relief’s common stock, to acquire all outstanding shares of AdVita. In addition, Relief will pay milestone payments of up to EUR 20 million in cash, contingent to achievement of certain regulatory milestones related to AdVita’s development programs.
DeZwarteRidder
0
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting
Ad Hoc Announcement pursuant to Art. 53 LR,

22 July 2021
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting

Shares being used in part for payments related to AdVita and APR acquisitions
Acquisitions are part of Relief’s transformation into a fully integrated diversified commercial-stage pharmaceutical company

Geneva, Switzerland, July 22, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief” or the “Company”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the Company will, on or around July 27, 2021, issue 1,000,000,000 additional registered shares out of the authorized share capital approved by the Annual General Meeting on June 18, 2021. The new shares are fully subscribed at par value by the Company’s wholly owned subsidiary, Relief Therapeutics International SA, and will be listed on the SIX Swiss Exchange on or around July 28, 2021. Some of the shares will be used for contractually agreed payments to the respective sellers of AdVita Lifescience GmbH (“AdVita”) and APR Applied Pharma Research SA (“APR”): approximately 140,000,000 shares and 206,786,784 shares, respectively. The remaining new shares will be held as treasury shares for possible future financing transactions, acquisitions, general corporate purposes, and the settlement of possible future contingent milestone payments to the APR and AdVita sellers. The APR sellers are generally subject to a 75-day lock-up period and a subsequent leak-out schedule.
DeZwarteRidder
0

Relief Therapeutics Announces CHF 15 Million Private Placement
Ad Hoc Announcement pursuant to Art. 53 LR,

26 July 2021
Relief Therapeutics Announces CHF 15 Million Private Placement

Geneva, Switzerland, July 26, 2021 –RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that it has entered into a definitive agreement with two U.S. institutional investors to purchase in a private placement an aggregate of 71,428,572 shares of Relief common stock at a purchase price of CHF 0.21 per share. The aggregate gross proceeds from the private placement are expected to be approximately CHF 15 million, before deducting the placement agent fees and offering expenses payable by Relief. The private placement offering is expected to close on or about July 28, 2021, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Relief plans to use the net proceeds from the private placement to acquire additional assets to expand and diversify its drug pipeline, meet its obligations to pay potential milestone payments and for general corporate purposes.

Jack Weinstein, Chief Financial Officer and Treasurer of Relief, said: “This financing provides us with significant additional flexibility to both meet our potential future milestone payments for Acer Therapeutics Inc., APR Applied Pharma Research SA and AdVita Lifescience GmbH, while also expanding our ability to grow our pipeline. Chief among our priorities is moving ahead with our plan to further the development of RLF-100TM worldwide, as vaccine acceptance issues and new COVID-19 variants make the need for an effective therapy as great as ever.”

The private placement shares will be trading on the SIX Swiss Exchange and ranking pari passu (carrying the same rights) with Relief’s existing shares, and will be delivered from Relief’s treasury shares that were issued out of its authorized share capital under exclusion of the existing shareholders’ pre-emptive rights.
Gerardke
0
Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE® KRUNCH in Germany and Italy
Bijlage:
DeZwarteRidder
0
quote:

Gerardke schreef op 9 september 2021 23:08:


Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE® KRUNCH in Germany and Italy


lol

Dat gaat Relief redden.....!!!
Gerardke
0
[quote alias=DeZwarteRidder id=13669074 date=202109092315]
[...]

lol

Dat gaat Relief redden.....!!!

I quote "Freek"

www.youtube.com/watch?v=H6uPe7Euzd8&a...
DeZwarteRidder
0
quote:

Gerardke schreef op 10 september 2021 08:40:


[quote alias=DeZwarteRidder id=13669074 date=202109092315]
[...]lol
Dat gaat Relief redden.....!!!
I quote "Freek"
www.youtube.com/watch?v=H6uPe7Euzd8&a...


Freek Vonk.....???
Kleintje66
2
Het is toch wel grappig dat het verbreden van de portfolio de eerste kleine resultaten begint op te leveren.
vastbijter
1
jazeker, al wel zo 3 a 4 jaar geleden, en sinds aantal maanden met Relief, kwestie van gewoon jou commentaar negeren. doe eens niet zo onaardig tegen iedereen, zelfs al heb je weleens gelijk, een gelukkig mens is niet onaardig.
Kleintje66
0
Iemand bij yahoo kwam dit melden:
Mystery solved! The 8K Sept 10 filing tells us why the overloaded regional hospitals had such a high death rate for VIP and placebo patients. The 8K says: "This data suggest that the IL-6 cytokine data document biologic effect across all patients and sites, even though the ultimate therapeutic result is dependent upon state-of the-art ICU care and specifically dependent upon not terminating life support on salvageable patients for the purposes of resource allocation." So the ICU's turned off the life support!

-----De patiënten die aviptadil kregen in het onderzoek zouden de behandeling gestopt hebben gekregen omdat minder zieke patiënten de beademing nodig hadden.
8.668 Posts, Pagina: « 1 2 3 4 5 6 ... 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 15 okt 2021 17:31
Koers 0,098
Verschil -0,005 (-4,85%)
Hoog 0,103
Laag 0,097
Volume 14.656.068
Volume gemiddeld 14.125.519
Volume gisteren 12.711.471

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront